Company intelligence / Profile preview

Combined Therapeutics

Boston, Massachusetts, United Statescombinedtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has demonstrated preclinical proof-of-concept for its MOPCTx platform, showing the ability to target antigen expression to specific tissues while protecting vital organs. Collaborative research with Boston Children’s Hospital and Harvard Medical School supports the technology’s potential. No human clinical results reported as of May 2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA therapeuticsmRNA vaccines
Industry: Biotech

Drug pipeline

1 asset

CTX-472

Preclinical

Partnerships

Boston Children’s HospitalHarvard Medical School (academic collaborations/partnerships)

Beyond the preview

Go deeper on Combined Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Combined Therapeutics.

Explore the full profile